

Executive Offices Direct Line: 020 7288 3589 www.whittington.nhs.uk The Whittington Hospital NHS Trust Magdala Avenue London N19 5NF

Whittington Health Trust Board

19 December 2012

Title:	Report of the Quality Committee held on Wednesday 21 st November 2012					
Agenda item:	6	Paper	С			
Action requested:	For noting					
Executive Summary:	The purpose of this paper is to inform Trust Board of the ke issues discussed at the Quality Committee on Friday 21 November 2012, advise of any concerns with regard to Qualit and Safety and provide assurance to the Board on the Trust Governance systems.					
		d Quarterly reports from a r of which are outlined in app				
	The following concerns were raised by the committee and additional information sought.					
	 The increasing trend in the number of complaints received in the past 3 quarters particularly in the Emergency Department and the lack of progress being made to meet the target for complaints responses A backlog of health assessments for children in care in Haringey – lack of assurance from the current actions as described by the divisional staff Safeguarding children training – lack of assurance on the accuracy of the numbers of relevant staff who have completed levels 2 and 3 training The quality of divisional reports regarding risk mitigation improvement and innovation – the committee is concerned that the reports in their current format do not 					
		anaged and appropriate a e or reduce the risk.	actions are in			
Summary of recommendations:	which are shown in App	highlighted a number of hot endix 1. The Trust Board is approve the recommenda	asked to			

0,			hittee is a sub Committee of the Trust Board rust Board on issues relating to Quality, Governance.					
	Reference to related / other documents:Minutes of the Qua November 2012.				Quality Committee held on Wednesday 21 st 2.			
Date paper con	npleted	l:	5 th December 2012					
Dire		Dire and	nagh Scott - ector of Nurs Patient erience		Director nam title:	e and	Sue Rubenste Non Executive – Chair of Qua Committee	e Director
Date paper seen by EC	16 th Octo ber 2012	Ass	ality Impact essment pplete?	N/A	Risk assessment undertaken?	N/A	Legal advice received?	N/A



Hot Spots Highlighted at Quality Committee Friday 21st November 2012

The Quality Committee met on Wednesday 21st November 2012 and received a number of reports from Divisions and sub-committees. (appendix 1a Agenda)

Key areas of discussion included:

• **Divisional reports** based on clinical risk, improvements and innovations – The committee has requested more comprehensive reports at future committee meetings outlining the actions being taken to mitigate all risks with a score of 12 or above. Additional guidance will be issued regarding the requirements by the committee. The main issues of risk highlighted include:

ICAM

District Nursing – Incidence of grade 3 & 4 pressure ulcers – although there has been a decrease these remain high. It was however noted that Whittington Health is not considered to be an outlier and work is ongoing to identify suitable Trust to benchmark with.

ED – Increasing complaints over the past 3 quarters and ongoing issues in relation to nurse staffing and use of agency nurses to backfill vacant posts. A number of recruitment days have been arranged in December and a nurse staffing skill mix review is underway.

HMP Pentonville – ongoing issues with complaints and the challenges facing access to health services for prisoners.

Sickness absence – There has been an increase in sickness absence in recent months which is currently under review.

MSK and Podiatry Waiting Times – Issues are related to increased demand, patient choice and the impact of the flooding of Trust facilities several months ago which has reduced capacity to see patients. Discussions are on going with commissioners in relation to podiatry services.

Women Children and Families

Theatre capacity in labour ward – A business case for an additional theatre is being developed. Additional capital money from NHSL is available until end of march 2013.

Impact of CIPs on the provision of therapy service to children – Discussions are ongoing with commissioners re level of service commissioned

New Born Visits – While much improved remain below target.

Surgery cancer and Diagnostics

Point of care Testing – Business case has been approved for additional staff who are in the process of being appointed

Bariatric Surgery – By its nature this is a high risk service. Complaints about the service are mainly in relation to administrative processes and flow which are being addressed. While there issues which have been identified following investigations into recent Sis an recent external review of the service has concluded that it is safe. There is currently an ongoing investigation into an SI with external representation on the investigating panel.

Cancer delays – Failure to meet the cancer targets is in someway related to patient choice regarding appointments and follow up however actions are in place and it is expected that the situation will improve in the near future.

- **CQC Quality and Risk Profiles** there were no additional areas of concern of which the Trust was not already aware and taking action to address.
- **Report on Falls Prevention** the ongoing improvement and reduction in the number of falls was noted by the committee.

- Aggregated Report for Complaints Incidents and Litigation for Quarter 2 2012 The committee noted the trend over the past 3 quarters of an increase in the number of complaints received and asked divisions to address actions in their reports to the committee in January 2013. In particular the committee asked the ICAM division to outline specific actions being taken to understand and address the increase in complaints about the Emergency Department.
- **Patient Experience Quarter 2 Report** the committee was appraised and assured of actions taken to implement the infrastructure to support the collection of data related to the Friends and Family Test from April 2013.
- **Biannual Report of the Drugs and Therapeutics Committee** received and noted.
- **Report from Haringey Children in Care Team** The Committee requested additional information from the Women Children and Family Division in January 2013 regarding actions being implemented to address the backlog in Children in Care Assessments.
- Safeguarding Children Quarterly Report for Quarter 2 The committee was assured that 88.8% of Trust staff have attended level 1 Child Protection training, and a plan is in place to understand levels 2 and 3 figures by the end of December 2012. The division has been asked to provide an update on levels 2 and 3 for the Committee in January 2013.
- **Operational Statement for Research** was approved with minor amendments. This is attached at Appendix 2 and requires ratification by the Board.
- Safeguarding Adults Quarterly Report received and noted.
- Infection Prevention and Control Quarterly Report Quarter 2 received and noted.

The Committee noted the approval of the Trust's Inquest Policy.

NIHR Guideline B01 R&D Operational Capability Statement

Version History

Version number RDOCS 001	Valid from	Valid to	Date approved	Approved by XX	Updated by XX

Contents

Organisation R&D Management Arrangements Organisation Study Capabilities Organisation Services Organisation R&D Interests Organisation R&D Planning and Investments Organisation R&D Standard Operating Procedures Register Planned and Actual Studies Register Other Information

Organisation R&D Management Arrangements

Information on key contacts

Organisation Details						
Name of Organisation	Whittington Health					
R&D Lead / Director (with responsibility for reporting on R&D to	Robert Sherwin					
the Organisation Board)						
Key Contact Details e.g. Research Governance Lead, NHS Perr	missions Signatory contact details					
Contact 1:						
Role:	R&D Director					
Name:	Dr Robert Sherwin					
Contact Number:	0207 288 5414					
Contact Email:	robert.sherwin@nhs.net					
Contact 2:						
Role:	Assistant Director					
Name:	Dr. Senga Steel					
Contact Number:	020 7288 3405					
Contact Email:	senga.steel@nhs.net					
Contact 3:						
Role:	RM&G Administrator					
Name:	Sanela Andrijac					
Contact Number:	020 7288 3274					
Contact email:	sanela.andrijac@nhs.net					
Contact 4:						
Role:						
Name:						
Contact Number:						
Contract email						
Add further lines as required						

Go to top of document

Information on staffing of the R&D Office

R&D Team		
R&D Office Roles	Whole Time Equivalent	Comments
(e.g. Governance, Contracts, etc)		indicate if part time/full time/shared/joint etc
R&D Director		Part time. RM&G strategy lead and RM&G issues
Assistant Director	0.5	Part time. Role deals with all RM&G issues
RM&G Administrator & PA to Assistant Director of Research +	1.0	Role deals with all RM&G issues
Research and Director of Research + Innovation	1.0	

Add further lines as required

Information on reporting structure in organisation (include information on any relevant committees, for example, a Clinical Research Board / Research Committee / Steering Committee.)

Reporting Structures

There is a Research Management and Governance Executive Committee that oversees the functions and systems for the approval and support of Research across the organisation. This committee reports to the Quality Committee, a sub committee of Trust Board.

Go to top of document

Information on Research Networks supporting/working with the Organisation.

Information on how the Organisation works with the Comprehensive Local Research Network (CLRN), Primary Care Research Network (PCRN), Topic Specific Clinical Research Networks (TCRN)

Research Networks	
Research Network (name/location)	Role/relationship of the Research Network eg host Organisation
Central and East London Comprehensive Local Research	Member
Network	
North London Cancer Network	Host site for Cancer Network studies
Diabetese Network	Host site for Diabetes Network studies
Stroke Network	Host site for Stroke Network studies
Go to top of document	

Go to top of document

Information on collaborations and partnerships for research activity (e.g. BRC, BRU, Other NHS Organisations, Higher Education Institutes, Industry)

Current Collaborations / Partnerships				
Organisation Name	Details of Collaboration / Partnership (eg University/Organisation Joint Office, external provider of pathology services to Organisation, etc, effective dates)	Contact Name	Email address	Contact Number
UCL/UCLH Comprehensive Biomedical Research Centre	Research Support Services Managed by Joint Research Unit (UCLH, UCL and RFH)			
	Research Support Services Managed by Joint Research Unit (UCLH, UCL and RFH)			
	Research Support Services Managed by Joint Research Unit (UCLH, UCL and RFH)			
North London Cancer Research Network	Running of studies		NLCRNadmin@cancer.ucl.ac.uk	
UCL Partners	UCL			

Organisation Study Capabilities

Information on the types of studies that can be supported by the Organisation to the relevant regulatory standards

Types of Studies Organisation has capabilities in (please tick applicable)							
	CTIMPs	Clinical Trial of a Medical	Other Clinical Studies	Human Tissue: Tissue	Study Administering	Qualitative Study	OTHER
	(indicate Phases)	Device		Samples Studies	Questionnaires		
As Sponsoring Organisation	No	No	Yes - single site	No	Yes	Yes	Any single site study apart from CTIMPS
As Participating Organisation	All phases other than phase 1	All phases	Yes	Yes	Yes	Yes	All types of studies except primary care
As Participant Identification Centre	All phases	All phases	Yes	Yes	Yes	Yes	All types of studies
Add further lines as required						-	

Go to top of document

Which licences does the organisation hold which may be relevant to research?

Organisation Licences			
Licence Name	Licence Details	Licence Start Date (if applicable)	Licence End Date (if applicable)
Example: Human Tissue Authority Licence			
None			
So to top of document			

Go to top of document

PCT ONLY: Information on the practices which are able to conduct research

Number/notes on General Practitioner (GP) Practices
N/A

Organisation Services

Information on key clinical services contacts and facilities/equipment which may be used in studies for suporting R&D governance decisions across the organisation.

Simical Service Departments		O and a st Nisser a within	Operator at a secol	O such set us work su	Details of any internal arms and the selector
Service Department	Specialist facilities that may be provided (eg number/type of scanners)		Contact email	Contact number	Details of any internal agreement templates
		Service Department			
Pathology	Routine Haematological and Blood Transfusion testing	TBC	senga.steel@nhs.net	020 7288 3274	
Pharmacy	Specialist facilities that may be provided/standard service (Brief)	Priyal Shah and Simon	senga.steel@nhs.net		
	Pharmacy clinical trials service includes:	Wan			
	 Managing IMP at site which includes receipt, storage (including 				
	temperature monitoring), dispensing, returns, destruction (if				
	necessary) of IMP			020 7288 3274	
	 Maintaining pharmacy file which includes trial-specific pharmacy 				
	SOPs, IMP accountability, patient-specific IMP accountability / returns				
	- IMP may be intravenous cytotoxic chemotherapy, oral chemotherapy				
	or other oral medication.				
Radiology	Plain x-ray, fluroscopy, ultrasound, CT scans, MRI, nuclear medicine,	Recep Saleyman	senga.steel@nhs.net	020 7288 3274	
	mammography, DEXA			020 1200 3214	

Go to top of document

Information on key management contacts for suporting R&D governance decisions across the organisation.

Management Support e.g. Finance, Legal Services, Archiving					
Department			Contact email	Contact number	Details of any internal agreement templates
		Service Department			
Archiving	All WH studies are archived in line with UCLH/UCL archiving policy	R&D	senga.steel@nhs.net	020 7288 3274	
Contracts	Access to UCLH contracts team for advice and guidance	R&D	senga.steel@nhs.net	020 7288 3274	
Finance	Assistance with costs and budgeting of studies	Eleanor Hellier	eleanor.hellier@nhs.net		
HR	Assistance with HR work within RM&G. Research passport	Sanela Andrijac	sanela.andrijac@nhs.net	020 7288 3274	
Statistical support	Statistical support provided by Biostatistics Group at UCLH.	Mark Griffin	mark.griffin@ucl.ac.uk		

Organisation R&D Interests

Information on the areas of research interest to the Organisation

Organisation R&D Areas of Interest						
Area of Interest	Details	Contact Name	Contact Email	Contact Number		
Cancer	Host site for North London Cancer Network. Specific areas of interest	-		020 7288 3405		
Cardiovascular			senga.steel@nhs.net	020 7288 3405		
Cellular and Gene Therapy			senga.steel@nhs.net	020 7288 3405		
Continence			senga.steel@nhs.net	020 7288 3405		
Diabetes			senga.steel@nhs.net	020 7288 3405		
Gastroenteroloyg and Hepatology			senga.steel@nhs.net	020 7288 3405		
Haematology			senga.steel@nhs.net	020 7288 3405		
Imaging			senga.steel@nhs.net	020 7288 3405		
Infectious Diseases			senga.steel@nhs.net	020 7288 3405		
Neurodegeneration			senga.steel@nhs.net	020 7288 3405		
Neurodiagnostics			senga.steel@nhs.net	020 7288 3405		
Neuroimaging			senga.steel@nhs.net	020 7288 3405		
Neurotherapeutics			senga.steel@nhs.net	020 7288 3405		
Nursing, Midwifery and AHP research			senga.steel@nhs.net	020 7288 3405		
Oral Health			senga.steel@nhs.net	020 7288 3405		
Respiratory, anethetics and critical care			senga.steel@nhs.net	020 7288 3405		
Womens Health			senga.steel@nhs.net	020 7288 3405		
Add further lines as required		1				

Add further lines as require Go to top of document

Information on Local / National Specialty group membership within the Organisation which has been shared with the CLRN

Specialty Group Membership (Local and National)						
National / Local	Specialty Group	Specialty Area (if only specific areas within group)	Contact Name	Contact Email	Contact Number	
Martin Kuper	Critical Care Specialty Group	Enhanced recovery and critical care				
Hugh Montgomery	Critical Care Specialty Group	Critical care				
Jayant Vaidya	Cancer Network	Breast cancer and surgical intervention				
Farrukh Shah	Thalasaemia	Thalasaemia				
Pauline Leonard	Cancer Network	Cancer				

Organisation R&D Planning and Investments

Planned Investment				
Area of Investment	Description of Planned Investment	Value of Investment	Indicative dates	
(e.g. Facilities, Training, Recruitment, Equipment etc.)		value of investment		
ReDA database	Merging of EPS into ReDA database which will allow for tracking, monitoring and recruitment of all clinical studies	~£2000	Jun-12	
Add further lines as required				

Organisation R&D Standard Operating Procedures Register

Standard Operating Procedures				
SOP Ref Number	SOP Title	SOP Details	Valid from	Valid to
We have a suite of SOPs which are currently being updated in line with RSS.	Protocol amendments	Management and approval of protocol amendments	02/02/2012	02/02/2014
	Serious breeches	Statutory management of serious protocol breeches under EU Law	02/02/2012	02/02/2014
			02/02/2012	02/02/2014
			02/02/2012	
	Consent for research	Outlines responsibilities of standards in line with ICH-GCP	02/02/2010	02/02/2012
	Auditng of research studies	Process by which studies are selected and audited under research	02/02/2012	02/02/2014
	Site file guidance	SOP on setting up and maintating study records	09/09/2012	09/09/2014
	Sponsorship approval	guidance for investigators for submitting proposals to Whittington health for	09/06/2012	09/09/2014
	Approval of Commerical studies	Process by which commerical stideos are approved	Under development	
	Research passport approval	process for agremement of passports and letters of access	Under development	
	management of research fraud and misconduct	How fraud and misconduct are managed -outlines responsibilities of	In progress	02/02/2014

Add further lines as required

Go to top of document

Information on the processes used for managing Research Passports

Indicate what processes are used for managing Research Passports

All research passport requests and letters of access are handled by the R&D administrator.

Add further lines as required

Go to top of document

Information on the agreed Escalation Process to be used when R&D governance issues cannot be resolved through normal processes

Escalation Process

The R and D administrator will escalate any issues to the Assistant Director of Research, Innovation and Quality. If the issue cannot be resolved it will be escalated to the Director of Research at Whittington Health. If appropriate, unresolved issues should be referreed to Cheif Executive Office of Whittington Health.

Add further lines as required Go to top of document

Go to top of document

Other Information

For example, where can information be found about the publications and other outcomes of research which key staff led or callaborated in?

Other Information (relevant to the capability of the Organisation)

The Whittington prides itself in running a range of study types, phase and complexity. Recuitment into NIHR adopted studies between the financial year of 2011-2012 was 536; an extra 200 patients and staff were recruited into the non-portfolio. There are currently 138 studies actively recruiting withing the trust involving approximately 100 researchers. As well as partaking in multi-centred national studies, there is a drive for locally lead ideas, service evaluations, innovation and collaborations between the expanding Whittington Health. There is a close working relationship with the Middlesex University, promoting research within the nursing population looking at patient benefit and staff working relationships, environment and streamlining. An annual research and development report is published and is published externally on the trust website

Add further lines as required Go to top of document